Transperineal 125Iodine implantation for treatment of clinically localized prostate cancer: 5-Year tumor control and morbidity

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 3, 1999, Pages 565-570

  Storey, Mark R ^a   Landgren, Robert C ^b   Cottone, Joseph L ^d   Stallings, J Walt ^c   Logan, Charles W ^c   Fraiser, Lacy P ^c   Ross, Cynthia S ^b   Kock, Robert J ^e   Berkley, Lawrence W ^f   Hauer Jensen, Martin ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PA   (United States)

^c Urology Associates   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Ctrl AR Radiation Therapy Institute   (United States)

^f NONE

Author keywords

Community results; Prostate cancer; Transperineal implants

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIOISOTOPE THERAPY; SURVIVAL TIME; TREATMENT OUTCOME; BLOOD; BRACHYTHERAPY; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE;

EID: 0032587881     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00451-9     Document Type: Article

References (24)

1. Landis S.H., Murray T., Bolden S., et al. Cancer Statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Russell K.J., Blasko J.C. Recent advances in interstitial brachytherapy for localized prostate cancer. Probl Urol. 7:1993;260-279.
3. Blasko J.C., Radge H., Schumacher D. Transperineal percutaneous Iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurietherapy Hyperthermia Oncol. 3:1987;131-139.
4. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
5. Altman D.G. Practical statistics for medical research. 1991;179-268 Chapman and Hall, London.
6. Harris E.K., Albert A. Survivorship analysis for clinical studies. 1991;5-125 Marcel Dekker, Inc, New York.
7. Cox D.R., Oakes D. Analysis of survival data. 1984;110-120 Chapman and Hall, London.
8. Rainwater L.M., Morgan W.R., Klee G.G., et al. Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc. 65:1990;1118-1126.
9. 125I prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
10. 125Iodine implantation for Stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
11. Kupelian P., Levin H., Zippe C., et al. A contemporary series of external beam radiotherapy versus radical prostatectomy for localized prostate cancer A single institution experience . Proc Annu Meet Am Soc Clin Oncol. 15:1996;A616.
12. Partin A., Pound C.R., Quentin Clemens J., et al. Serum PSA after anatomic radical prostatectomy The Johns Hopkins experience after 10 years . Urol Clin North Am. 20:1993;713-725.
13. Roach M. III, Burton E., Kroll S., et al. 501 men irradiated for clinically localized prostate cancer (1987-1995): Preliminary analysis of the experience at UCSF and affiliated facilities. Int J Radiat Oncol Biol Phys. 36:(Suppl):1996;248.
14. Zagars G.K., Pollack A. Radiation therapy for T1 and T2 prostate cancer Prostate-specific antigen and disease outcome . Urology. 45:1995;476-483.
15. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
16. Killian C.S., Yang N., Emrich L.J., et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res. 45:1985;886-891.
17. Stamey T.A., Kapalin J.N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. J Urol. 141:1989;1070-1075.
18. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine-125 implantation for T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
19. Fowler F.J., Barry M.J., Lu-Yao G., et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience 1988-1990 . Urology. 42:1993;622-629.
20. Jonler M., Messing E.M., Rhodes P.R., et al. Sequelae of radical prostatectomy. Br J Urol. 74:1994;352-358.
21. Murphy G.P., Mettlin C., Menck H., et al. National patterns of prostate cancer by radical prostatectomy Results of a survey by the American college of surgeons commission on cancer . J Urol. 154:1995;1100-1101.
22. Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997; 39:347-353.
23. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 40:1998;1111-1115.
24. Critz F.A., Levinson A.K., Williams W.H., et al. The PSA Nadir that indicates potential cure after radiotherapy for prostate cancer. Urology. 49:1997;322-326.